Place des nouveaux traitements de l'ostéodystrophie rénale : dérivés 1α-hydroxylés de la vitamine D « non hypercalcémiants », complexants non calciques, non magnésiens et non aluminiques des phosphates, et calcimimétiques

Ghazali A, Charoud A, Oprisiu R, Fournier A. Aspects cliniques, physiopathologiques et thérapeutiques. Encyclopedie médico-chirurgicale Elsevier SAS. Paris Nephrologie 18-061-D-10:23p, 2003. Malluche, 1976, Bone histology in incipient and advanced renal failure, Kidney Int., 9, 355, 10.1038/ki.1976.42 Albright, 1937, Renal osteitis fibrosa cystica: report of a case with discussion of metabolic aspects, Bulletin John Hopkins Hospital, 60, 377 Parfitt, 2003, Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry, Curr. Opin. Nephrol. Hypertens., 12, 387, 10.1097/00041552-200307000-00007 Oprisiu, 2003, Pathologie osseuse et insuffisance rénale. Actualités sur les explorations biologiques: bone disease and renal failure. Updating biochemical markers, Immuno-analyse et biologie spécialisée, 18, 67, 10.1016/S0923-2532(03)00003-6 Block, 2004, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis, J. Am. Soc. Nephrol., 15, 2208, 10.1097/01.ASN.0000133041.27682.A2 Cohen Solal, 1991, Comparison of intact, midregion, and carboxy terminal assays of parathyroid for the diagnosis of bone disease in hemodialyzed patients, J. Clin. Endocrinol. Metab., 73, 516, 10.1210/jcem-73-3-516 Fournier, 2001, Optimal range of plasma concentration of true 1-84 parathyroid hormone in patients on maintenance dialysis, J. Clin. Endocrinol. Metab., 86, 1840, 10.1210/jc.86.4.1840 Souberbielle, 2003, The use in clinical practice of parathyroid hormone normative values established in vitamin D-sufficient subjects, J. Clin. Endocrinol. Metab., 88, 3501, 10.1210/jc.2003-030097 Gonzalez, 1996, Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells, Kidney Int., 50, 63, 10.1038/ki.1996.287 Lund, 2004, Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model, J. Am. Soc. Nephrol., 15, 359, 10.1097/01.ASN.0000109671.99498.08 2003, (Kidney Disease Outcomes Quality Initiative) of the National Kidney Foundation, Am J Kidney Dis Chertow, 2002, Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients, Kidney Int., 62, 245, 10.1046/j.1523-1755.2002.00434.x Fournier, 1995, Optimal plasma concentrations of intact parathyroid hormone in predialysis patients, Nephrol. Dial. Transplant., 10, 2376, 10.1093/ndt/10.12.2376 Torres, 1995, Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH, Kidney Int., 47, 1434, 10.1038/ki.1995.201 Reichel, 1991, Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism, Nephrol. Dial. Transplant., 6, 162, 10.1093/ndt/6.3.162 Panda, 2001, Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction, Proc. Natl. Acad. Sci. USA, 98, 7498, 10.1073/pnas.131029498 Masuyama, 2003, Dietary calcium and phosphorus ratio regulates bone mineralization and turnover in vitamin D receptor knockout mice by affecting intestinal calcium and phosphorus absorption, J. Bone Miner. Res., 18, 1217, 10.1359/jbmr.2003.18.7.1217 Dusso, 2003, Vitamin D receptor: mechanisms for vitamin D resistance in renal failure, Kidney Int. Suppl., S6, 10.1046/j.1523-1755.63.s85.3.x Cozzolino, 2003, Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia, Kidney Int., 64, 1653, 10.1046/j.1523-1755.2003.00284.x Cozzolino, 2001, p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium, Kidney Int., 60, 2109, 10.1046/j.1523-1755.2001.00042.x Silver, 2001, 25 Liu, 1943, Studies of calcium phosphate metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron, Medicine, 22, 103, 10.1097/00005792-194305000-00002 Portale, 1987, Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D, J. Clin. Invest., 80, 1147, 10.1172/JCI113172 Llach, 1985, On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency, J. Clin. Endocrinol. Metab., 61, 601, 10.1210/jcem-61-4-601 Fournier, 1982, Prevention and medical treatment of hyperparathyroidism secondary to renal failure in the adult, 241 Moriniere, 1983, Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism, Proc. Eur. Dial. Transplant Assoc., 19, 784 Ward, 1978, Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminium, Lancet, 1, 841, 10.1016/S0140-6736(78)90191-5 Christiansen, 1978, Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol, Lancet, 2, 700, 10.1016/S0140-6736(78)92702-2 Bayard, 1973, Plasma 25-hydroxycholecalciferol in chronic renal failure, Eur. J. Clin. Invest., 3, 447, 10.1111/j.1365-2362.1973.tb02213.x Eastwood, 1976, Vitamin D deficiency in the osteomalacia of chronic renal failure, Lancet, 1209, 10.1016/S0140-6736(76)91140-5 Fournier, 1988, Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3, Kidney Int. Suppl., 24, S178 Lafage, 1992, Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy, Kidney Int., 42, 1217, 10.1038/ki.1992.407 Lafage Proust, 1999, Bone mass and dynamic parathyroid function according to bone histology in non dialyzed uremic patients after long term protein and phosphorus resctriction, J. Clin. Endocrinol. Metab., 84, 512, 10.1210/jc.84.2.512 Combe, 1994, Phosphorus and protein restriction and parathyroid function in chronic renal failure, Kidney Int., 46, 1381, 10.1038/ki.1994.408 Delmez, 1989, Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium, J. Clin. Invest., 83, 1349, 10.1172/JCI114022 Memmos, 1982, Response of uremic osteoid to vitamin D, Kidney Int. Suppl., 11, S50 Fournier, 1979, Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization, Kidney Int., 15, 196, 10.1038/ki.1979.25 Fraser, 1970, Unique biosynthesis by kidney of a biological active vitamin D metabolite, Nature, 228, 764, 10.1038/228764a0 Cheng, 2004, Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase, Proc. Natl. Acad. Sci. USA, 101, 7711, 10.1073/pnas.0402490101 St-Arnaud, 2000, Deficient demineralisation of intramembranous bone in vitaimn D-24-hydroxylase-ablated mice is due to elevated 1.25 dihydroxy vitamin D and not to the absence of 24.25 dihydroxy vitamin D, Endocrinology, 141, 2658, 10.1210/en.141.7.2658 Kinuta, 2000, Vitamin D is a negative regulating factor in bone mineralisation, J. Bone Miner. Res., 15, s180 Holick, 2004, Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task, J. Clin. Endocrinol. Metab., 89, 3149, 10.1210/jc.2004-0682 Chapuy, 1992, Vitamin D3 and calcium to prevent hip fractures in the elderly women, N. Engl. J. Med., 327, 1637, 10.1056/NEJM199212033272305 LaClair, 2005, Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States, Am. J. Kidney Dis., 45, 1026, 10.1053/j.ajkd.2005.02.029 Cannata-Andia, 2002, Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure, Nephrol. Dial. Transplant., 17, 1875, 10.1093/ndt/17.11.1875 Ghazali, 1999, Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol?, Kidney Int., 55, 2169, 10.1046/j.1523-1755.1999.00480.x Segersten, 2002, 25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands, J. Clin. Endocrinol. Metab., 87, 2967, 10.1210/jc.87.6.2967 Johnson, 1974, Prevention and reversal of progressive secondary hyperparathyroidism in patients maintained by hemodialysis, Am. J. Med., 56, 827, 10.1016/0002-9343(74)90811-0 Fournier, 1992, Use of alkaline calcium salts as phosphate binder in uremic patients, Kidney Int. Suppl., 38, S50 Indridason, 2000, Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group, Kidney Int., 57, 282, 10.1046/j.1523-1755.2000.00819.x Moriniere, 1992, Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia, Nephron, 60, 6, 10.1159/000186697 Sadek, 2003, Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study, Nephrol. Dial. Transplant., 18, 582, 10.1093/ndt/18.3.582 Bommer, 2004, Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am. J. Kidney Dis., 44, 661, 10.1053/j.ajkd.2004.06.008 Fournier, 1971, Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. I. Association of bone disease with potentially etiologic factors, J. Clin. Invest., 50, 592, 10.1172/JCI106529 Fournier, 1971, Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. II. Factors affecting serum immunoreactive parathyroid hormone, J. Clin. Invest., 50, 599, 10.1172/JCI106530 Delmez, 1992, Calcium acetate as a phosphorus binder in hemodialysis patients, J. Am. Soc. Nephrol., 3, 96, 10.1681/ASN.V3196 Ben Hamida, 1993, Long-term (6 months) cross-over comparisonof calcium acetate with calcium carbonate as phosphate-binder, Nephron, 63, 258, 10.1159/000187207 Fournier, 1997, 96 London, 2004, Arterial calcifications and bone histomorphometry in end-stage renal disease, J. Am. Soc. Nephrol., 15, 1943, 10.1097/01.ASN.0000129337.50739.48 Hamdy, 1995, Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, 310, 358, 10.1136/bmj.310.6976.358 Ritz, 1995, Low-dose calcitriol prevents the rise of 1-84 PTH without affecting serum calcium and phosphate in patients with moderate renal failure, Nephrol. Dial. Transplant., 10, 2228, 10.1093/ndt/10.12.2228 Rix, 2004, Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure, Nephrol. Dial. Transplant., 19, 870, 10.1093/ndt/gfg595 Fournier, 1995, 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration, Nephron, 71, 254, 10.1159/000188732 Coyne, 2004, Paricalcitol (Zemplar capsule controls secondary hyperparathyroidism in CKD stage 3 and 4 patients, J. Am. Soc. Nephrol., 15, 733A Berl, 1978, 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study, Ann. Intern. Med., 88, 774, 10.7326/0003-4819-88-6-774 Baker, 1986, Controlled trial of calcitriol in hemodialysis patients, Clin. Nephrol., 26, 185 Hayashi, 2004, Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial, Nephrol Dial Transplant, 19, 2067, 10.1093/ndt/gfh329 Teng, 2003, Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy, N. Engl. J. Med., 349, 446, 10.1056/NEJMoa022536 Teng, 2005, Activated injectable vitamin D and hemodialysis survival: a historical cohort study, J. Am. Soc. Nephrol., 16, 1115, 10.1681/ASN.2004070573 Shoji, 2004, Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population, Nephrol. Dial. Transplant., 19, 179, 10.1093/ndt/gfg513 Ishimura, 1999, Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure, Kidney Int., 55, 1019, 10.1046/j.1523-1755.1999.0550031019.x Holick, 2004, Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease, Am. J. Clin. Nutr., 80, 1678S, 10.1093/ajcn/80.6.1678S Bachschmid, 2005, A new"sunshine" in the vasculature?, Circulation, 111, 1572, 10.1161/01.CIR.0000161830.45399.F6 Somjen, 2005, 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds, Circulation, 111, 1666, 10.1161/01.CIR.0000160353.27927.70 Li, 2002, 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system, J. Clin. Invest., 110, 229, 10.1172/JCI0215219 Porsti, 2004, High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure, Kidney Int., 66, 2155, 10.1111/j.1523-1755.2004.66006.x Haffner, 2005, Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3, J. Hypertens., 23, 1067, 10.1097/01.hjh.0000166849.72721.1c Phan, 2004, Sevelamer prevents accelerated atherosclerosis in apolipoprotein E deficient (apoE-/-) mice with chronic renal failure (CRF) 5 Abstract, J. Am. Soc. Nephrol., 15, 275A Milliner, 1990, Soft tissue calcification in pediatric patients with end-stage renal disease, Kidney Int., 38, 931, 10.1038/ki.1990.293 Goodman, 2000, Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis, N. Engl. J. Med., 342, 1478, 10.1056/NEJM200005183422003 Goldsmith, 1997, Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis, Nephron, 77, 37, 10.1159/000190244 Renaud, 1988, Evaluation of vascular calcinosis risk factors in patients on chronic hemodialysis: lack of influence of calcium carbonate, Nephron, 48, 28, 10.1159/000184864 Fournier, 1997, The clinical significance of adynamic bone disease in uremia, 131 Marangella, 1993, Effects of oral and intravenous calcitriol on serum calcium oxalate saturation in dialysis patients, Clin. Sci. (Lond.), 85, 309, 10.1042/cs0850309 Canavese, 2005, Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients, Am. J. Kidney Dis., 45, 540, 10.1053/j.ajkd.2004.10.025 Kazama, 2005, Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients, Kidney Int., 67, 1120, 10.1111/j.1523-1755.2005.00178.x Nakanishi, 2005, Serum fibroblast grouth factor-23 levels predict future refactory hyperparathyroïdism in dialysis patients, Kidney Int., 67, 1171, 10.1111/j.1523-1755.2005.00184.x Braun, 2004, Long-term comparison of a calcium-free phosphate-binder and calcium carbonate-phosphorus metabolism and cardiovasculair calcification, Clin. Nephrol., 62, 104, 10.5414/CNP62104 Raggi, 2005, Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis, J. Bone Miner. Res., 20, 764, 10.1359/JBMR.041221 Yang, 2004, Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro, Kidney Int., 66, 2293, 10.1111/j.1523-1755.2004.66015.x Duan, 1999, Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone, J. Clin. Endocrinol. Metab., 84, 718, 10.1210/jc.84.2.718 Epstein, 2005, The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy, Mayo Clin. Proc., 80, 379, 10.4065/80.3.379 Riggs, 2005, Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling, J. Bone Miner. Res., 20, 177, 10.1359/JBMR.041114 Atsumi, 1999, Risk factors for vertebral fractures in renal osteodystrophy, Am. J. Kidney Dis., 33, 287, 10.1016/S0272-6386(99)70302-1 Piraino, 1988, Fractures and vertebral bone mineral density in patients with renal osteodystrophy, Clin. Nephrol., 30, 57 Coco, 2000, Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone, Am. J. Kidney Dis., 36, 1115, 10.1053/ajkd.2000.19812 Faugere, 1986, Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis, J. Lab. Clin. Med., 107, 481 Johnell, 2005, Predictive value of BMD for hip and other fractures, J. Bone Miner. Res., 20, 1185, 10.1359/JBMR.050304 Chertow, 2003, Effect of sevelamer or calcium acetate on proxies of atherosclérotic and arteriosclerotic vascular disease in hemodialysis patients, Am. J. Nephrol., 23, 307, 10.1159/000072822 Coladonato, 2002, Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients, Adv. Ren. Replace. Ther., 9, 193, 10.1053/jarr.2002.34842 Qunibi, 2004, Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study), Kidney Int., 65, 1914, 10.1111/j.1523-1755.2004.00590.x McCullough, 2004, Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review, J. Nephrol., 17, 205 London, 2003, Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality, Nephrol. Dial. Transplant., 18, 1731, 10.1093/ndt/gfg414 Manns, 2004, A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States, Kidney Int., 66, 1239, 10.1111/j.1523-1755.2004.00877.x Date, 2003, Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients, Nephrol. Dial. Transplant., 18, iii90 Damment, 2004, The bone kinetics of lanthanum in dialysis patient treated with lanthanum carbonate up to 45 years (Abstract), J. Am. Soc. Nephrol., 15, 271A Malluche, 2004, No osteomalacia in dialysis patients treated with lanthanum carbonate up to 4.5 years (Abstract), J. Am. Soc. Nephrol., 15, 270A Hergesell, 1999, Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients, Nephrol. Dial. Transplant., 14, 863, 10.1093/ndt/14.4.863 Yang, 2002, An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate, Nephrol. Dial. Transplant., 17, 265, 10.1093/ndt/17.2.265 Hergesell, 2002, Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics, Nephrol. Dial. Transplant., 17, 14, 10.1093/ndt/17.1.14 Capuzzi, 1998, Efficacy and safety of an extended-release niacin (Niaspan): a long-term study, Am. J. Cardiol., 82, 74U, 10.1016/S0002-9149(98)00731-0 Shimada, 1996, Niceritorol increases serum phosphate levels in hemodialyzed patients. A randomized double blind cross over study, J. Am. Soc. Nephrol., 7, 52 Katai, 1999, Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine, Nephrol. Dial. Transplant., 14, 1195, 10.1093/ndt/14.5.1195 Takahashi, 2004, Nicotinamide suppresses hyperphosphatemia in hemodialysis patients, Kidney Int., 65, 1099, 10.1111/j.1523-1755.2004.00482.x Canner, 1986, Fifteen year mortality in coronary drug project patients: long-term benefit with niacin, J. Am. Coll. Cardiol., 8, 1245, 10.1016/S0735-1097(86)80293-5 Gale, 2004, For the ENDIT group: European Nicoticotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type I diabetes, Lancet, 363, 925, 10.1016/S0140-6736(04)15786-3 Rutkowski, 2003, N-methyl-2-pyridone-5-carboxamide: a novel uremic toxin?, Kidney Int. Suppl., S19, 10.1046/j.1523-1755.63.s84.36.x Chiarugi, 2003, Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders, J. Neurochem., 85, 306, 10.1046/j.1471-4159.2003.01684.x Jagtap, 2005, Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors, Nat. Rev. Drug Discov., 4, 421, 10.1038/nrd1718 Hofer, 2003, Extracellular calcium sensing and signalling, Nat. Rev. Mol. Cell Biol., 4, 530, 10.1038/nrm1154 Block, 2004, Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis, N. Engl. J. Med., 350, 1516, 10.1056/NEJMoa031633 Fournier, 2004 Moe, 2003, Long term treatment of secondary hyperparathyroidism (HTP) with the calcimimetic cinacalcet, J. Am. Soc. Nephrol., 14, 463 Cunningham, 2005, Effect of the calcimimetic cinacalcet HCl on cardiovascular disease fracture, and health-related quality of life in secondary hyperparathyroidism, Kidney Int, 68, 1793, 10.1111/j.1523-1755.2005.00596.x Henley, 2005, 1,25(OH) vitamin D but not cinacalcet treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism, Nephrol. Dial. Transplant., 20, 1370, 10.1093/ndt/gfh834 Young, 2004, Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS), Am. J. Kidney Dis., 44, 34, 10.1016/S0272-6386(04)01103-5 Moe, 2005, Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl, Kidney Int., 67, 760, 10.1111/j.1523-1755.2005.67139.x Neer, 2001, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N. Engl. J. Med., 344, 1434, 10.1056/NEJM200105103441904 Ishii, 2000, Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia, Bone, 26, 175, 10.1016/S8756-3282(99)00263-X Frazao, 2004 Charytan, 2005, Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis, Am. J. Kidney Dis., 46, 58, 10.1053/j.ajkd.2005.04.013 Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroïdectomy on renal graft function, blood pressure and serum lipids in Kidney Transplant recipients: a simple center study. Nephrol. Dial. Transplant. 2005; (In press). Kruse, 2005, The calcimimetic cinacalcet normalizes serum calcium in renal transplant with persistent hyperparathyroïdism, Nephrol. Dial. Transplant., 20, 1311, 10.1093/ndt/gfh924 Serra, 2005, Successful treatment of hypercalcemia wiht Cinacalcet in renal transplant recipients with persistent hyperparathyroïdism, Nephrol. Dial. Transplant., 20, 1315, 10.1093/ndt/gfh925